Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE) (NCT06843239)
A Phase 2, Multi-Center Study Consisting of a Randomized, Double-Blind, Placebo-Controlled Period, Followed by an Open-Label Extension Period, to Assess the Efficacy, Safety, and Tolerability of Tibulizumab in Adults With Systemic Sclerosis
🩺 Plain-English Summary (8th-Grade Level)
The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 24 weeks (Period 1) in adult participants with systemic sclerosis, followed by an open-label extension period where all active participants will receive tibulizumab and will be evaluated for an additional 28 weeks (Period 2)
Who can join: Review the eligibility criteria below.
Location: UCSD Altman Clinical and Translational Research Institute Center for Clinical Research — La Jolla, California
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (60 Sites)
Showing the first 25 of 60 sites.
- UCSD Altman Clinical and Translational Research Institute Center for Clinical Research — La Jolla, California
- UCLA Department of Medicine — Los Angeles, California
- IRIS Research and Development LLC — Plantation, Florida
- University of Iowa — Iowa City, Iowa
- Massachusetts General Hospital — Boston, Massachusetts
- University of Michigan Hospital — Ann Arbor, Michigan
- Rheumatology Associates — Arlington, Texas
- STAT Research S.A. — Buenos Aires, Buenos Aires
- Centro de Investigaciones Médicas Tucumán — San Miguel de Tucumán, Tucumán Province
- Organización Médica de Investigación — Buenos Aires,
- Centro de Investigación y Prevención Cardiovascular-Arenales — Buenos Aires,
- Hospital General de Agudos Dr. José María Ramos Mejia — Buenos Aires,
- Instituto de Investigación Clínica TyT — Buenos Aires,
- Centro Medico de Estudios Clinicos y Farmacovigilancia (CECYF) — Buenos Aires,
- Consultorios Médicos Dr. Doreski — Buenos Aires,
- Consultora Integral de Salud Centro Médico Privado — Córdoba,
- Instituto CER S.A. — Quilmes,
- AES - AS - Clinica Mayo de Urgencias — San Miguel de Tucumán,
- CTR Estudios Clinicos — Santiago,
- Enroll SpA — Santiago,
- Centro de especialidades médicas Vanguardia — Temuco,
- Clinical Research Chile SpA — Valdivia,
- Centro de Estudios Clinicos Victoria Limitada (Cevic) — Victoria,
- Dermacross Clinica Dermatologica — Vitacura,
- Debreceni Egyetem Klinikai Kozpont Nagyerdei Campus — Debrecen,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Systemic Sclerosis (SSc)
- Mycophenolate After Stem Cell Transplant for Systemic Sclerosis — Ottawa, Ontario
- Intralesional Injection of STS in Treatment of Calcinosis — Pittsburgh, Pennsylvania
- A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis — Phoenix, Arizona
- Quantification of Calcinosis Cutis Disease Burden Using Computed Tomography Images — New Haven, Connecticut
- Systemic Sclerosis DIet for GastrointESTinal Symptoms — Ann Arbor, Michigan
Explore by condition: All Systemic Sclerosis (SSc) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.